A large cohort, "the TP53-CRC-international collaborative study", which is a meta-analysis study analyzing more than 3,500 CRC patients from 17 countries, also demonstrated that Dukes' C tumors with wild-type TP53 showed a significantly better survival when treated with postoperative adjuvant chemotherapy [38]. The gene discussed is TP53; the disease is colorectal carcinoma.